鼠抗人hMIC-l单克隆抗体抑制裸鼠移植人胰腺癌体内研究

目的：初步研究鼠抗人hMIC-l单克隆抗体对胰腺癌体内给药的抗肿瘤活性，为hMIC-l抗体应用于肿瘤治疗提供实验依据。方法2种人胰腺癌细胞株PANC-1和SW1990各腋窝皮下接种24只Balb/c裸鼠，共计48只皮下接种荷瘤裸鼠分别随机共分为8组，每组6只荷瘤鼠。模型对照组荷瘤裸鼠腹腔注射0.9％氯化钠注射液（10 mL/kg，NS，Biw，ip ×8），阳性对照组荷瘤裸鼠腹腔注射键择（50 mg/kg，qw，ip ×4），鼠抗人hMIC-l单克隆抗体组分别荷瘤鼠尾静脉内注射鼠抗人hMIC-l单克隆抗体（10 mg/kg，Biw，ip ×8）共4周或（2 mg/kg，Biw，ip ×8）共4周。观察荷瘤裸鼠日常表现、肿瘤生长、实验后肿瘤组织切片HE染色后光镜下的组织形态学改变。结果荷瘤裸鼠尾静脉内注射鼠抗人hMIC-l单克隆抗体组裸鼠（10 mg/kg，Biw，iv ×8）肿瘤生长缓慢，瘤体明显小于模型对照组，并呈现量效关系。镜下观察鼠抗人hMIC-l单克隆抗体组实验后肿瘤组织切片胰腺结构破坏，有大量淋巴细胞浸润，肿瘤细胞明显坏死，细胞溶解。结论尾静脉内注射鼠抗人hMIC-l单克隆抗体（10 mg/kg，Biw，iv ×8）能有效抑制裸鼠移植人胰腺癌PANC-1肿瘤生长，使瘤组织坏死、结构破坏。

Effective of anticancer mouse monoclonal antibody against hMIC-1 targets pancreatic tumor for nude mice in vivo

Objective To investigate a antitumor effects of mouse original monoclonal antibody against hMIC -1 as intravenous administration with human pancreatic tumor in vivo and providing experimental data .Methods The fourty-eight mice were randomized into eight groups for loaded with two pancreatic tumor cell lines panc -1 or sw1990 respectively , and individual tumor growth was observed , antitumor efficacy was evaluated after using mouse original monoclonal antibody against hMIC-1 by intravenous administration .The pathological change with formalin fixed , paraffin embedded tissues section was viewed .Results There was a significant difference in tumor volume and weigt in intravenous injection of mouse original monoclonal antibody against hMIC-1 on load pancreatic tumor with nude mice group compared with that in＆amp;nbsp;the control group after four week treatment , and the mouse original monoclonal antibody against hMIC-1 demonstrated a close association between inhibition of tumor volume growth and dose-effective in the two xenograft models examined .Under examined microscope , the pancreatic tumor tissue was destroyed evidently in mouse original monoclonal antibody against hMIC-1 group.Conclusions The antitumor effect of intravenous injection for mouse original monoclonal antibody against hMIC-1 is better than that of systemic using gemcitabine .